OnKure Therapeutics, Inc.
OKUR
$2.82
-$0.015-0.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 06/30/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 3.34% | 215.26% | 285.47% | 220.63% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 18.97% | 72.92% | 80.47% | 58.92% | |
| Operating Income | -18.97% | -72.92% | -80.47% | -58.92% | |
| Income Before Tax | -8.85% | -67.00% | -84.47% | -72.79% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -8.85% | -67.00% | -84.47% | -72.79% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -8.85% | -67.00% | -84.47% | -72.79% | |
| EBIT | -18.97% | -72.92% | -80.47% | -58.92% | |
| EBITDA | -19.09% | -73.74% | -81.37% | -59.45% | |
| EPS Basic | 97.46% | 96.09% | -92.64% | -7,164.99% | |
| Normalized Basic EPS | 97.34% | 96.09% | -82.01% | -6,846.51% | |
| EPS Diluted | 97.46% | 96.09% | -92.64% | -7,164.99% | |
| Normalized Diluted EPS | 97.34% | 96.09% | -82.01% | -6,846.51% | |
| Average Basic Shares Outstanding | 4,181.81% | 4,175.25% | -4.23% | -97.62% | |
| Average Diluted Shares Outstanding | 4,181.81% | 4,175.25% | -4.23% | -97.62% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |